Investors Can Lead in Ultragenyx Pharmaceutical Inc. Securities Fraud Opportunity

February 6, 2026

Investors who purchased Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE) securities during the period between August 3, 2023, and December 26, 2025, are being reminded by The Schall Law Firm, a nationally recognized shareholder rights litigation firm, about a class action lawsuit concerning alleged violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission.

Individuals affected by losses during the mentioned Class Period are advised to contact the firm before April 6, 2026. The Company was said to have portrayed a falsely positive outlook on the impact of its drug candidate on patients with Osteogenesis Imperfecta (“OI”) and misled investors by failing to achieve a statistically significant reduction in annualized fracture rate (“AFR”) during the Phase III ORBIT study. Consequently, revelations about Ultragenyx’s misconduct led to financial losses for investors.

To seek recovery for such losses, investors are encouraged to participate in the case. The Schall Law Firm specializes in representing investors globally in securities class action lawsuits and shareholder rights litigation matters.

Please note that the class has not yet been certified, which means you are not presently represented by an attorney. In case you decide not to take any action, you retain the option of remaining an absent class member. The firm’s contact information is provided for your convenience, and consultations regarding your rights are offered at no cost.

It is crucial to understand that any statements from Ultragenyx relating to the effects of its drug candidate during the class period were allegedly false and materially deceptive. The Company’s misleading representation of the drug’s efficacy contributed to false impressions in the market, ultimately leading to financial repercussions for investors once the actual facts about Ultragenyx’s activities were disclosed.